Does longer duration of corticosteroid treatment improve clearance in vulvar lichen sclerosus? Results from a single centre, comparative, open label study

A complete clearance of vulvar lichen sclerosus (VLS) is achieved in a minority of patients treated with a standard 12‐week duration corticosteroid treatment. The aim of this pragmatic, retrospective, open label, comparative trial was to assess the effectiveness, in terms of complete clearance, of a 24‐week treatment with mometasone furoate 0.1% ointment (MMF) and to compare it with a 12‐week therapy. We included VLS patients treated with MMF administered for five consecutive days/week for 24 weeks (group A). The following were assessed: (a) clearance in Global Subjective Score (GSS), Global Objective Score (GOS) or both, (b) changes of these parameters and dyspareunia at treatment completion compared to baseline, (c) safety profile. All these assessments were compared with the same outcomes recorded among VLS patients who had previously undergone a 12‐week MMF treatment (group B). Twenty‐nine patients were included in group A and 32 in group B. The rates of patients who achieved the clearance of GSS, GOS or both parameters did not significantly differ between groups A and B. The groups did not differ in any of the effectiveness outcomes assessed. A 24‐week duration corticosteroid treatment does not seem to provide significant therapeutic benefits in comparison with standard 12‐week courses, especially considering the occurrence of complete clearance.